Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Peter A. Merkel, MD, MPH

University of Pennsylvania
Philadelphia, PA, United States

Dr. Merkel is the Chief of Rheumatology and a Professor of Medicine and Epidemiology at the University of Pennsylvania. Dr. Merkel is an internationally recognized research and clinical expert in vasculitis and scleroderma, two diseases he has studied for over 25 years, and is an author on over 400 scientific publications. He is the Principal Investigator of the Vasculitis Clinical Research Consortium (VCRC), a leading international research infrastructure for vasculitis clinical investigation. Dr. Merkel’s research focuses on clinical trial design and conduct, outcome measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery.

Dr. Merkel received his MD from Yale University, his MPH from Harvard University, completed his residency training at the Hospital of the University of Pennsylvania and his fellowship at the Massachusetts General Hospital/Harvard Medical School. Dr. Merkel receives the majority of his research support from the National Institutes of Health, the US Food and Drug Administration, the Patient-Centered Outcomes Research Institute, with additional funding from industry sources and private foundations.

Presentation(s):

  • 0683: Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • 0684: Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • Introduction to the Project and Rationale for Developing Criteria for Response for ANCA-Associated Vasculitis

    Monday, November 13, 2023
    7:30 AM – 7:40 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • Validation of Response Criteria and Next Steps/Implementation

    Monday, November 13, 2023
    8:10 AM – 8:20 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • L14: Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • 235: Exploring New Frontiers: CAR T Cell Therapy in Autoimmune Diseases

    Tuesday, November 14, 2023
    6:00 PM – 8:00 PM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)

  • The Evolution of Clinical Research in Vasculitis: Lessons Learned for the Study of Rare Diseases

    Wednesday, November 15, 2023
    9:15 AM – 10:00 AM PT

    Disclosure(s): AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); ArGenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing); HiBio: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Jubilant: Consultant (Ongoing); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); MiroBio: Consultant (Ongoing); Neutrolis: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing); Visterra: Consultant (Ongoing)